<DOC>
	<DOCNO>NCT01597700</DOCNO>
	<brief_summary>Bioequivalence study compare test Acotral® ezetimibe 10 mg tablet manufacture Laboratorios Phoenix , reference comparator Zetia® ezetimibe 10 mg tablet Merck/Schering-Plough Pharmaceuticals . The CRO Clinigene Bangalore , conduct study . Fifty two healthy adult subject satisfied inclusion exclusion criterion give informed consent enter study . They fast receive one tablet mouth accordance randomisation list blood sample take specified interval ensue 3 day . Between 14 21 day later , subject receive opposite tablet clinical process repeat . Subjects continuously monitor trial clinic ambulatory visit regular measurement vital sign question adverse event . Drug concentration analyse result compare ascertain bioequivalence apply statistical method pharmacokinetic data ; information safety data formally report .</brief_summary>
	<brief_title>Acotral® Versus Zetia® Ezetimibe Bioequivalance Study .</brief_title>
	<detailed_description>This randomize , balance , open label , crossover , two period , two treatment , two sequence , single dose bioequivalence study compare test Acotral® ezetimibe 10 mg tablet manufacture Laboratorios Phoenix , Argentina reference comparator Zetia® ezetimibe 10 mg tablet Merck/Schering-Plough Pharmaceuticals , USA . The CRO Clinigene International Ltd , Bangalore , India conduct study . Fifty two healthy male adult subject satisfied inclusion exclusion criterion give write informed consent enter study . They fast overnight receive one tablet mouth accordance randomisation list venous blood sample take specified interval ensue 3 day ; meal water ad libitum allow . Between 14 21 day later , subject return clinic follow procedure receive opposite tablet clinical process repeat . Subjects continuously safety monitor trial clinic ambulatory visit regular measurement vital sign question adverse event accordance trial clinic SOPs . Drug concentration analyse result compare accordance study protocol ascertain bioequivalence apply statistical method pharmacokinetic data ; information safety data formally report GSK .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Literate healthy adult male human subject within age range 18 45 year inclusive . Weight le 50 kg . Normal BMI [ 18.5 24.99 kg/m2 inclusive ] . Willingness provide write informed consent participate study capable give write informed consent participate study . Free significant disease clinically significant abnormal finding screen , medical history , physical examination , laboratory evaluation , 12lead ECG , Chest Xray [ PA view ] . AST , ALT , alkaline phosphatase bilirubin 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Absence disease marker HIV 1 2 , Hepatitis B C Syphilis . ECG normal morphology measurement . QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . History presence significant : Cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease . History presence significant : Alcohol dependence , alcohol abuse past one year . Drug abuse last one month illicit drug last 6 month . Smoking 5 cigarette per day consumption form tobacco contain product . Asthma , urticaria allergic type reaction take aspirin drug . Ulceration history gastric / duodenal ulcer . Jaundice past 6 month . Bleeding disorder . Allergy test drug drug chemically similar drug excipients product investigation . Donation 500 mL blood within 08 week prior receive first dose study drug . Subjects participate another clinical study past 3 month prior commencement study . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study assessment compromise subject safety . Any difficulty accessibility forearm vein cannulation blood sampling . Refuse abstain food least 10 h prior drug administration least 4 h dose period . Refuse abstain fluid least 1 h prior 1 h post dose . Found positive breath alcohol test do day checkin ambulatory visit . Found positive urine test drug abuse do day checkin . History difficulty swallow tablet . Use enzyme modifying drug within 30 day prior receive first dose study medication . Other Eligibility Criteria Considerations To assess potential impact subject eligibility regard safety , investigator must refer product data sheet detailed information regard warning , precaution , contraindication , adverse event , significant data pertain product use study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>